KLI

Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease

Metadata Downloads
Abstract
Background Sodium-glucose co-transporter 2 inhibitors reduce the risk of cardiovascular events in type 2 diabetic patients with coronary artery disease (CAD); however, the underlying mechanisms remain unclear. Objectives We compared the effects of empagliflozin vs. sitagliptin therapy on myocardial perfusion reserve (MPR) using dynamic single-photon emission computed tomography (SPECT) imaging. Methods In total, 100 patients with type 2 diabetes, CAD and an MPR <2.5 were randomized to receive either empagliflozin (10 mg once daily) or sitagliptin (100 mg once daily). Dynamic SPECT examinations were performed at baseline and at 6 months. The primary endpoint was the percent change of global MPR. Evaluable SPECT data were available for 98 patients. Results Baseline clinical characteristics and SPECT data were well balanced between the two groups. At a 6-month follow-up, the fasting glucose and glycated hemoglobin levels significantly decreased in both groups. Hematocrit and hemoglobin levels significantly increased in the empagliflozin group but not in the sitagliptin group. The global MPR significantly improved after treatment in both groups (34.5 +/- 70.6%; P = 0.005 for empagliflozin vs. 22.4 +/- 45.7%; P = 0.024 for sitagliptin). However, there was no significant difference in the global MPR between the two groups (P = 0.934). Similar findings were detected with regard to the regional MPR. Conclusion Among patients with type 2 diabetes and CAD, both empagliflozin and sitagliptin significantly improved the global MPR with no significant difference between the groups.
Author(s)
김선옥문대혁안정민오민영이철환이필형최준호
Issued Date
2021
Type
Article
Keyword
Benzhydryl CompoundsCare and treatmentComparative analysisCoronary Artery DiseaseCoronary heart diseaseDiabeticsEpidemiologyGlucosidesGlycosylated hemoglobinHumansMedical collegesMiddle AgedMyocardial Perfusion ImagingSitagliptinSitagliptin PhosphateSPECT imagingTomographyEmission-ComputedSingle-PhotonType 2 diabetes
DOI
10.1097/MNM.0000000000001429
URI
https://oak.ulsan.ac.kr/handle/2021.oak/8272
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_proquest_miscellaneous_2561924598&amp;context=PC&amp;vid=ULSAN&amp;lang=ko_KR&amp;search_scope=default_scope&amp;adaptor=primo_central_multiple_fe&amp;tab=default_tab&amp;query=any,contains,Comparison%20of%20empagliflozin%20and%20sitagliptin%20therapy%20on%20myocardial%20perfusion%20reserve%20in%20diabetic%20patients%20with%20coronary%20artery%20disease&amp;offset=0&amp;pcAvailability=true
Publisher
NUCLEAR MEDICINE COMMUNICATIONS
Location
미국
Language
한국어
ISSN
0143-3636
Citation Volume
42
Citation Number
9
Citation Start Page
972
Citation End Page
978
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.